Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert G Kiss

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Heart Rhythm|September 11, 2013
Exercise-induced vasovagal syncopeAdam Bőhm, Robert G Kiss, Bela Bachmann, et al.
Cardiology Journal|June 28, 2017
Refined heart failure detection algorithm for improved clinical reliability of OptiVol alerts in CRT-D recipientsMate Vamos, Noemi Nyolczas, Zsolt Bari, et al.
The Canadian Journal of Cardiology|April 3, 2009
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapyBela Merkely, Emese Tóth-Zsamboki, David Becker, et al.
The American Journal of Cardiology|February 16, 2016
Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50)David D Berg, Marc P Bonaca, Eugene Braunwald, et al.
Lancet (London, England)|September 1, 2009
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trialMarc S Sabatine, Elliott M Antman, Petr Widimsky, et al.
Circulation|September 5, 2015
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50Erin A Bohula, Philip E Aylward, Marc P Bonaca, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 2, 2012
Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin studyAdam D Tarnoki, David L Tarnoki, Pal Bata, et al.
JACC. Cardiovascular Interventions|August 24, 2019
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCIStefan H Hohnloser, Philippe Gabriel Steg, Jonas Oldgren, et al.
JAMA Cardiology|September 1, 2025
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical TrialSiddharth M Patel, Robert P Giugliano, David A Morrow, et al.
European Heart Journal. Acute Cardiovascular Care|October 21, 2020
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategyBatric Popovic, Emmanuel Sorbets, Jeremie Abtan, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Heart Rhythm|September 11, 2013
Exercise-induced vasovagal syncopeAdam Bőhm, Robert G Kiss, Bela Bachmann, et al.
Cardiology Journal|June 28, 2017
Refined heart failure detection algorithm for improved clinical reliability of OptiVol alerts in CRT-D recipientsMate Vamos, Noemi Nyolczas, Zsolt Bari, et al.
The Canadian Journal of Cardiology|April 3, 2009
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapyBela Merkely, Emese Tóth-Zsamboki, David Becker, et al.
The American Journal of Cardiology|February 16, 2016
Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50)David D Berg, Marc P Bonaca, Eugene Braunwald, et al.
Lancet (London, England)|September 1, 2009
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trialMarc S Sabatine, Elliott M Antman, Petr Widimsky, et al.
Circulation|September 5, 2015
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50Erin A Bohula, Philip E Aylward, Marc P Bonaca, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 2, 2012
Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin studyAdam D Tarnoki, David L Tarnoki, Pal Bata, et al.
JACC. Cardiovascular Interventions|August 24, 2019
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCIStefan H Hohnloser, Philippe Gabriel Steg, Jonas Oldgren, et al.
JAMA Cardiology|September 1, 2025
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical TrialSiddharth M Patel, Robert P Giugliano, David A Morrow, et al.
European Heart Journal. Acute Cardiovascular Care|October 21, 2020
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategyBatric Popovic, Emmanuel Sorbets, Jeremie Abtan, et al.
Pageof 3